Hwang Angela 4

4 · PFIZER INC · Filed Feb 24, 2023

Form 4

Period: 2023-02-22

Group President

Transactions

Exercise/Conversion
Common Stock
2023-02-22$30.17/sh+57,032$1,720,655→ 67,027 total
Tax Payment
Common Stock
2023-02-22$42.38/sh−8,041$340,778→ 58,986 total
Award
Stock Appreciation Rights
2023-02-23+89,920→ 89,920 total
Exercise: $42.30From: 2030-02-23Exp: 2030-02-23→ Common Stock (89,920 underlying)
Tax Payment
Common Stock
2023-02-22$43.70/sh−34,718$1,517,177→ 24,268 total
Exercise/Conversion
Stock Appreciation Rights
2023-02-22−57,032→ 0 total
Exercise: $30.17From: 2023-02-22Exp: 2023-02-22→ Common Stock (57,032 underlying)
Award
Stock Appreciation Rights
2023-02-23+103,320→ 103,320 total
Exercise: $42.30From: 2028-02-23Exp: 2028-02-23→ Common Stock (103,320 underlying)

Holdings

Footnotes (7)

[F1]The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
[F2]The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
[F3]The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
[F4]Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
[F5]The reporting person disclaims beneficial ownership of the shares held by spouse.
[F6]The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
[F7]The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

Documents

1 file